304 related articles for article (PubMed ID: 24408116)
1. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
Van Buren PN; Adams-Huet B; Nguyen M; Molina C; Toto RD
Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116
[TBL] [Abstract][Full Text] [Related]
2. Serum potassium in dual renin-angiotensin-aldosterone system blockade.
Seliger SL; Fried LF
Clin J Am Soc Nephrol; 2014 Feb; 9(2):219-21. PubMed ID: 24408119
[No Abstract] [Full Text] [Related]
3. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
Mehdi UF; Adams-Huet B; Raskin P; Vega GL; Toto RD
J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893
[TBL] [Abstract][Full Text] [Related]
4. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
[TBL] [Abstract][Full Text] [Related]
5. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
6. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
7. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
Preston RA; Afshartous D; Garg D; Medrano S; Alonso AB; Rodriguez R
Hypertension; 2009 May; 53(5):754-60. PubMed ID: 19307466
[TBL] [Abstract][Full Text] [Related]
9. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
Weiss RJ; Stapff M; Lin Y
Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
[TBL] [Abstract][Full Text] [Related]
10. Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Fried LF; Emanuele N; Zhang JH; Brophy M; Conner TA; Duckworth W; Leehey DJ; McCullough PA; O'Connor T; Palevsky PM; Reilly RF; Seliger SL; Warren SR; Watnick S; Peduzzi P; Guarino P;
N Engl J Med; 2013 Nov; 369(20):1892-903. PubMed ID: 24206457
[TBL] [Abstract][Full Text] [Related]
11. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
12. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[TBL] [Abstract][Full Text] [Related]
14. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
[TBL] [Abstract][Full Text] [Related]
15. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
Bianchi S; Bigazzi R; Campese VM
Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
[TBL] [Abstract][Full Text] [Related]
16. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
17. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
18. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
19. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
20. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
